Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$60.1m

Vor Biopharma Management

Management criteria checks 3/4

Vor Biopharma's CEO is Robert Ang, appointed in Aug 2019, has a tenure of 5.33 years. total yearly compensation is $2.69M, comprised of 22.5% salary and 77.5% bonuses, including company stock and options. directly owns 0.86% of the company’s shares, worth $518.74K. The average tenure of the management team and the board of directors is 2.2 years and 4.4 years respectively.

Key information

Robert Ang

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage22.5%
CEO tenure5.3yrs
CEO ownership0.9%
Management average tenure2.2yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Dec 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

May 06

CEO Compensation Analysis

How has Robert Ang's remuneration changed compared to Vor Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$112m

Jun 30 2024n/an/a

-US$118m

Mar 31 2024n/an/a

-US$120m

Dec 31 2023US$3mUS$606k

-US$118m

Sep 30 2023n/an/a

-US$116m

Jun 30 2023n/an/a

-US$106m

Mar 31 2023n/an/a

-US$98m

Dec 31 2022US$5mUS$570k

-US$92m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$81m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$2mUS$508k

-US$70m

Sep 30 2021n/an/a

-US$70m

Jun 30 2021n/an/a

-US$65m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$424k

-US$49m

Compensation vs Market: Robert's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.

CEO

Robert Ang (49 yo)

5.3yrs

Tenure

US$2,691,044

Compensation

Dr. Robert Ang, MBBS, MBA, M.D., serves as Independent Non-Executive Director at Enara Bio Limited since September 2021 and serves as its Chairman since August 2024. He is the President, Chief Executive Of...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Ang
President5.3yrsUS$2.69m0.86%
$ 518.7k
Tirtha Chakraborty
Chief Scientific Officer4.1yrsUS$1.31m0.14%
$ 86.9k
Eyal Attar
Chief Medical Officer2.2yrsUS$1.40m0.015%
$ 9.0k
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Han Choi
Chief Financial Officerless than a yearno datano data
Amy Quinlan
Interim Principal Accounting Officerless than a yearno data0.042%
$ 25.1k
Tania Philipp
Chief People Officer5yrsno datano data
John King
Chief Commercial Officer & Head of Business Development4.3yrsno datano data
Samir Vattompadam
Senior Vice President of Portfolio Strategy & Program Management1.2yrsno datano data
David Phillips
Senior VP & Head of Quality1.2yrsno datano data

2.2yrs

Average Tenure

51yo

Average Age

Experienced Management: VOR's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Ang
President5.3yrsUS$2.69m0.86%
$ 518.7k
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
David Lubner
Independent Director4.4yrsUS$151.60k0%
$ 0
Matthew Patterson
Independent Chairman of the Board4.2yrsUS$185.60k0.0088%
$ 5.3k
Joshua Resnick
Independent Director5.8yrsUS$157.50k0%
$ 0
Eric Sievers
Scientific & Clinical Advisorno datano datano data
Sven Lundberg
Independent Director5.8yrsUS$152.10k0.043%
$ 25.7k
Daniella Beckman
Independent Director4.4yrsUS$164.10kno data
Steven Devine
Scientific & Clinical Advisorno datano datano data
Robert Soiffer
Scientific & Clinical Advisorno datano datano data
Hans-Peter Kiem
Scientific & Clinical Advisorno datano datano data
Soheil Meshinchi
Scientific & Clinical Advisor3.9yrsno datano data

4.4yrs

Average Tenure

53yo

Average Age

Experienced Board: VOR's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:48
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vor Biopharma Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Carter GouldBarclays
Justin WalshB. Riley Securities, Inc.